Table 1 Summary of 21 cancers identified in 21 patients
Tumor number | Histopathology | Pathologic size (cm) | Molecular subtype | Assessment | Tumor extent (cm) | L/B ratio | |||
|---|---|---|---|---|---|---|---|---|---|
99mTc sestamibi | 99mTc maraciclatide | 99mTc sestamibi | 99mTc maraciclatide | 99mTc sestamibi | 99mTc maraciclatide | ||||
1 | DCIS | 7.0 | Not applicable | 4 | 4 | 10.3 | 8.3 | 1.54 | 1.79 |
2 | IDC | 0.6 | Luminal | 1 | 1 | N/A | N/A | N/A | N/A |
3 | IDC | 0.7 | Luminal | 1 | 2 | N/A | N/A | 1.02 | 1.15 |
4 | IDC | 0.8 | Triple negative | 3 | 4 | 1.2 | 1.1 | 1.16 | 1.15 |
5 | IDC | 0.9 | Luminal | 4 | 4 | 1.1 | 1.3 | 1.29 | 1.37 |
6 | IDC | 1.2 | Luminal | 4 | 4 | 3.1 | 3.1 | 1.59 | 1.71 |
7 | IDC | 1.5 | HER-2 positive | 4 | 5 | 1.5 | 1.3 | 1.62 | 1.60 |
8 | IDC | 1.6 | HER-2 positive | 5 | 4 | 2.1 | 1.7 | 1.93 | 2.70 |
9 | IDC | 1.7 | Luminal | 4 | 4 | 1.0 | 1.8 | 1.12 | 1.11 |
10 | IDC | 1.8 | Triple negative | 4 | 5 | 1.7 | 1.3 | 1.71 | 1.67 |
11 | IDC | 2.6 | HER-2 positive | 4 | 4 | 3.0 | 3.0 | 2.02 | 1.62 |
12 | IDC | 3.5 | HER-2 positive | 4 | 4 | 7.0 | 7.5 | 1.27 | 1.30 |
13 | IDC | 5.2 | Luminal | 4 | 4 | 3.0 | 3.3 | 1.57 | 1.50 |
14 | IDC | 5.4 | Luminal | 4 | 4 | 5.9 | 2.7 | 1.31 | 1.61 |
15 | IDC | 7.0 | Luminal | 5 | 4 | 3.0 | 3.0 | 1.63 | 1.79 |
16 | IDC | 9.2 | Triple negative | 4 | 4 | 11.0 | 9.2 | 1.43 | 1.42 |
17 | Mixed IDC/ILC | 1.1 | Luminal | 4 | 4 | 1.0 | 1.1 | 1.41 | 1.55 |
18 | Mixed IDC/ILC | 1.6 | Luminal | 4 | 4 | 6.5 | 6.3 | 1.68 | 1.68 |
19 | Mixed IDC/ILC | 3.7 | Luminal | 4 | 4 | 2.8 | 5.4 | 2.17 | 2.07 |
20 | Mixed IDC/ILC | 13.1 | Luminal | 5 | 5 | 11.4 | 12.5 | 2.31 | 2.09 |
21 | ILC | 2.5 | Luminal | 1 | 4 | N/A | 9.3 | 1.15 | 1.49 |